Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.
about
Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapyTime trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational studyShould we treat acute HIV infection?Impact of human immunodeficiency virus type-1 sequence diversity on antiretroviral therapy outcomesA tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessationA novel substrate-based HIV-1 protease inhibitor drug resistance mechanismMinority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacyTransmitted minority drug-resistant HIV variants: a new epidemic?Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter CohortX4 tropic multi-drug resistant quasi-species detected at the time of primary HIV-1 infection remain exclusive or at least dominant far from PHISurveillance of transmitted antiretroviral drug resistance among HIV-1 infected women attending antenatal clinics in Chitungwiza, ZimbabweTransmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral loadTransmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapyFirst line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV-1 seroconverter studySpatial epidemiology of recently acquired HIV infections across rural and urban areas of North CarolinaA significant reduction in the frequency of HIV-1 drug resistance in Québec from 2001 to 2011 is associated with a decrease in the monitored viral loadDevelopment and customization of a color-coded microbeads-based assay for drug resistance in HIV-1 reverse transcriptasePersistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgroundsTransmitted Drug Resistance Mutations in Antiretroviral-Naïve Injection Drug Users with Chronic HIV-1 Infection in IranA Population-Structured HIV Epidemic in Israel: Roles of Risk and EthnicityTrends in Transmission of Drug Resistance and Prevalence of Non-B Subtypes in Patients with Acute or Recent HIV-1 Infection in Barcelona in the Last 16 Years (1997-2012)Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory TrialThe global spread of HIV-1 subtype B epidemic.Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs.Transmitted drug resistance in nonsubtype B HIV-1 infection.Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.Epidemiological study of phylogenetic transmission clusters in a local HIV-1 epidemic reveals distinct differences between subtype B and non-B infections.Provider-focused intervention increases adherence-related dialogue but does not improve antiretroviral therapy adherence in persons with HIVTransmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV-1-infected patients in South East Asia.Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men.Ten years survey of primary HIV-1 resistance in Serbia: the occurrence of multiclass resistance.A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimen.Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysisMinority variants of drug-resistant HIV.Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State.Characterization of drug-resistance mutations in HIV type 1 isolates from drug-naive and ARV-treated patients in Bulgaria.Primary drug resistance in South Africa: data from 10 years of surveys.HIV-1 antiretroviral resistance: scientific principles and clinical applicationsDrug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.
P2860
Q24243499-D1BFE1E3-430C-463D-BA49-B09B3C2C6F53Q24538955-AA427464-B203-4A85-AB9D-EBF47C21EC90Q26826523-F390D234-21DC-43E2-8E4D-5C5750D04377Q26851997-D16777B9-3783-4729-81FB-02968E755CAFQ27319650-488436BA-0919-4E5C-ADB4-974587E9D2A1Q28469113-41114CA2-6AE2-49D9-AD32-FAF632D0D549Q28473296-68F53067-85D2-43A4-8589-6271EA4A34CEQ28473302-A8D6233D-F503-4A37-8752-8E704F3F73EEQ28475698-746A747F-FC33-4E7B-B4E1-82CC058A671CQ28476667-1FC20919-9B05-405C-B478-395FCE69442EQ28478615-D8823385-C48C-4585-B730-B61C76E651E8Q28478656-3B624D24-8518-4BB7-92D5-5ACF4E1E6085Q28487475-BFCD15A3-B76D-4EB9-8475-CB28F42E1E75Q28538326-C10F9219-32BE-4AE8-B323-1ABABF672A87Q28539673-DD545CAD-03C3-4D45-9996-74D03D9734C5Q28543626-D9AD547D-6FA8-408C-92D3-7A6C32B72499Q28543768-B511E309-8A89-4622-A692-9624A209F32CQ28544845-63ADAED2-E807-45CE-8AA3-6900F4D383A3Q28547171-6A39D32C-008D-46DF-9BFE-F30F456FBE43Q28547440-9B317826-238C-4A88-91D6-E2FF0C58928AQ28547790-0317B7E0-8BBB-428B-94C6-06CD37981EFCQ28552171-62945AC1-72FA-47C3-A6EC-0F0A43842C83Q30388926-B811075F-248F-4B71-A920-F04A027B8565Q33483060-D5ADEFC6-04BC-4A50-8200-EAEA3888722BQ33567164-F238C87D-EE94-4292-B947-682AFF7F29F7Q33601530-FF858D0E-8D43-463A-9B9C-60C8772218F1Q33686402-7F9C1C13-6570-4174-9EAB-7FA903A3DF3BQ33703513-8BE7B2FA-891C-4C7B-BC13-346D53C99DB7Q33814896-97C43568-B1DA-480F-803E-65E0C403FC53Q33820125-1FC0F138-8C71-477F-9FE4-6B50A7B47185Q33821263-84AED675-9E04-4DF9-A2A3-08A14303C8F4Q33828355-0C2A1EE7-2934-4743-8460-F94F6FCEF21DQ33932293-E710FD3D-C453-4571-83F2-5C855153CC18Q33988153-0D486489-BBF7-4710-BC07-40A765EB06F7Q34047780-0E9E13CA-BA55-4E3C-BF59-B2F2969B19C1Q34079002-AD3C3A9C-3CC3-441E-A9BB-6E194CCEAF06Q34083250-B6175F7E-4E62-4DE6-960C-3A858E604063Q34129300-7C78CA87-1F1B-42A7-A013-45FF9D2AC7DCQ34280466-1E80DB10-BDE1-4A46-8A81-D80839CB350AQ34303603-F141C4AF-CC50-4359-A8AD-C5B08448E968
P2860
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Prevalence of drug-resistant H ...... tions for clinical management.
@en
type
label
Prevalence of drug-resistant H ...... tions for clinical management.
@en
prefLabel
Prevalence of drug-resistant H ...... tions for clinical management.
@en
P2093
P50
P356
P1476
Prevalence of drug-resistant H ...... tions for clinical management.
@en
P2093
Andrzej Horban
Andy Hoepelman
Angelos Hatzakis
Annemarie M J Wensing
Birgitta Asjö
Carmen de Mendoza
Charles A Boucher
Claudia Kücherer
Claus Nielsen
Clive Loveday
P304
P356
10.1086/432916
P407
P50
P577
2005-08-15T00:00:00Z